European estimates suggest only 1 in 14 PKU centers monitor bone in children while 3 in 5 monitor bone in adults. Frequency of monitoring is

unreported in the U.S. This study aims to use clinical parameters collected in PKU patients to predict total bone mineral density (BMD). METHODS: Data were collected from early-treated PKU patients over 4 years of age at baseline of a clinical trial (n = 57). Demographic (age, sex, BMI), clinical (phe prescription, medical-food prescription), laboratory (plasma phe and tyrosine, lipids, vitamin D), genetic (AV sum, a genetic mutation severity score), and dietary data were included. Correlation coefficients adjusted for age, sex, BMI, phe, and medical food intake were calculated between each parameter and total BMD, a reproducible

measure reflecting www.selleckchem.com/products/ars-1620.html average density of multiple sites. Predictors that correlated significantly with BMD and interactions terms were considered in models. Final models PX-478 clinical trial with (1) all data, (2) routine clinic visit data (excluding vitamin D, lipids), and (3) routine + genetic data were selected considering r-square and MSE. Categories of actual and predicted BMD z-scores were compared: normal [>−1stadard deviation (SD) from reference], at-risk (−2.5 to −1SD), and low (<−2.5SD). Future studies will collect variables Captisol included in models to validate predicted BMD and DXA-measured BMD (total, axial, and peripheral). RESULTS: In the sample (mean age = 17.3; 60 % male), 16 (28 %) had at-risk BMD; 3 (5 %) had low BMD. BMD was correlated with age, BMI, medical food prescription, cholesterol, triglycerides, vitamin D, and AV sum (p < 0.05). R-square values for final models ranged from 0.75 to 0.86 suggesting good fit. Models’ estimated BMD correlated with actual BMD [correlation coefficients (1) 0.93, (2) 0.87, (3) 0.91; p-value <0.0001] and predicted z-scores agreed with actual z-scores (kappa = 1.00; p-value <0.0001). CONCLUSIONS: Nearly one-third of study participants had BMD 1 SD below normal, and 3 had BMD Metalloexopeptidase at least 2.5 SD below normal. Routinely collected parameters

can predict total BMD and z-score category (normal, low, at-risk) in individuals with PKU. Each of the models can be used to identify patients at-risk for bone abnormalities without DXA expense and radiation exposure. Partial research support by BioMarin Pharmaceuticals and in part by PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources P17 DISAGREEMENT IN THE DIAGNOSIS OF OSTEOPENIA/OSTEOPOROSIS BY DUAL ENERGY X-RAY ABSORPTIOMETRY MEASUREMENTS WITH NORLAND INSTRUMENTS, BETWEEN DEVICE REFERENCE CURVES AND SELF-DEVELOPED REFERENCE CURVES, IN THE SPANISH FEMALE POPULATION Juan D. Pedrera-Zamorano, PhD, Metabolic Bone Diseases Research Group. University of Extremadura, CACERES, Spain; Jesus M. Lavado-Garcia, PhD, Metabolic Bone Diseases Research Group.